Vitrolife (Q2 review): Persisting growth headwind but expanding profitability - Redeye

Vitrolife's Q2 sales came in just below consensus at SEK857m but restructuring delivery drove EBITDA margins ahead of expectations coming in at 34%. The market read the report and buyback positively and the stock screens as "Attractively Priced" at a ~30% discount to Redeye's fair value.

Länk till analysen i sin helhet: https://www.redeye.se/research/1173695/vitrolife-q2-review-persisting-growth-headwind-but-expanding-profitability?utm_source=finwire&utm_medium=RSS